Cure My Disease

Don't miss your cure!

 Log in / Sign up

New weekly shot shows promise for rare low blood sugar disorder

NCT ID NCT04732416

Ongoing Disease control Sponsor: Hanmi Pharmaceutical Company Limited Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests a new medicine called HM15136 for people aged 2 and older with congenital hyperinsulinism (CHI) who still have low blood sugar despite standard treatments. The medicine is given as a weekly shot for 8 weeks. The goal is to see if it is safe and helps control blood sugar levels. About 16 participants will take part.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for CONGENITAL HYPERINSULINISM are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Congenital Hyperinsulinism familial hyperinsulinism

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

CONGENITAL HYPERINSULINISM

Contacts and locations

Locations

  • Asan Medical Center

    Seoul, South Korea

  • Central Manchester University Hospitals NHS Foundation Trust - Royal Manchester Children's Hospital - Centre for Paediatrics and Child Health

    Manchester, United Kingdom

  • Great Ormond Street Hospital (GOSH) for Children NHS Foundation Trust

    London, United Kingdom

  • Hadassah Medical Center (HMC)

    Jerusalem, Israel

  • Otto-von-Guericke-Universitaet Magdeburg

    Magdeburg, Germany

  • Pusan National University Yangsan Hospital

    Pusan, South Korea

  • The Children's Hospital of Philadelphia

    Philadelphia, Pennsylvania, 19104, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.